Almirall enters partnership with Inserm Transfert to research vitiligo

A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
by andreas lønstrup, translated by daniel pedersen

Spanish skin health firm Almirall has entered a licensing and research collaboration with Inserm Transfers, a private subsidiary of Inserm, which is the French National Institute of the Health and Medical Research, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading